Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fred R Hirsch

Showing results (31-40 of 405) with videos related to

Pageof 41
Sort By:
Current Opinion in Oncology|March 7, 2002
Chemoprevention strategies for non-small cell lung cancerNico van Zandwijk, Fred R Hirsch
The Lancet. Oncology|November 8, 2011
EGFR expression and the flexibility of FLEXFred R Hirsch, Roy S Herbst
Archives of Pathology & Laboratory Medicine|January 13, 2016
Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe?Keith M Kerr, Fred R Hirsch
Cancer Journal (Sudbury, Mass.)|December 10, 2020
Predictive Biomarkers for Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: Current Status and Future DirectionsSheena Bhalla, Deborah Blythe Doroshow, Fred R Hirsch
Current Opinion in Oncology|February 7, 2013
The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancerManolo D'Arcangelo, Murry W Wynes, Fred R Hirsch
Clinical Lung Cancer|July 28, 2009
The rationale and development of therapeutic insulin-like growth factor axis inhibition for lung and other cancersD Ross Camidge, Rafal Dziadziuszko, Fred R Hirsch
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 17, 2012
The mTOR pathway in lung cancer and implications for therapy and biomarker analysisSimon Ekman, Murry W Wynes, Fred R Hirsch
Journal of the National Comprehensive Cancer Network : JNCCN|March 11, 2018
Genomic Testing in Lung Cancer: Past, Present, and FutureCéline Mascaux, Ming-Sound Tsao, Fred R Hirsch
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 2, 2008
The insulin-like growth factor pathway in lung cancerRafal Dziadziuszko, D Ross Camidge, Fred R Hirsch
JAMA Oncology|January 1, 2016
Postprogression Prolongation of Survival in EGFR-Mutated Lung Cancer: Reconciling the ASPIRATION and IMPRESS TrialsDavid R Gandara, Mary Redman, Fred R Hirsch
Pageof 41

Showing results (31-40 of 405) with videos related to

Sort By:
Pageof 41
Current Opinion in Oncology|March 7, 2002
Chemoprevention strategies for non-small cell lung cancerNico van Zandwijk, Fred R Hirsch
The Lancet. Oncology|November 8, 2011
EGFR expression and the flexibility of FLEXFred R Hirsch, Roy S Herbst
Archives of Pathology & Laboratory Medicine|January 13, 2016
Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe?Keith M Kerr, Fred R Hirsch
Cancer Journal (Sudbury, Mass.)|December 10, 2020
Predictive Biomarkers for Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: Current Status and Future DirectionsSheena Bhalla, Deborah Blythe Doroshow, Fred R Hirsch
Current Opinion in Oncology|February 7, 2013
The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancerManolo D'Arcangelo, Murry W Wynes, Fred R Hirsch
Clinical Lung Cancer|July 28, 2009
The rationale and development of therapeutic insulin-like growth factor axis inhibition for lung and other cancersD Ross Camidge, Rafal Dziadziuszko, Fred R Hirsch
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 17, 2012
The mTOR pathway in lung cancer and implications for therapy and biomarker analysisSimon Ekman, Murry W Wynes, Fred R Hirsch
Journal of the National Comprehensive Cancer Network : JNCCN|March 11, 2018
Genomic Testing in Lung Cancer: Past, Present, and FutureCéline Mascaux, Ming-Sound Tsao, Fred R Hirsch
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 2, 2008
The insulin-like growth factor pathway in lung cancerRafal Dziadziuszko, D Ross Camidge, Fred R Hirsch
JAMA Oncology|January 1, 2016
Postprogression Prolongation of Survival in EGFR-Mutated Lung Cancer: Reconciling the ASPIRATION and IMPRESS TrialsDavid R Gandara, Mary Redman, Fred R Hirsch
Pageof 41